Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2026 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent...
June 25, 2026 04:30 ET | Source: SNS Insider pvt ltd

Breast Cancer Liquid Biopsy Market Size to Reach USD 3.42 Billion by 2035 | SNS Insider

Austin, United States, June 25, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Breast Cancer Liquid Biopsy Market Size was valued at USD 1.33 Billion in 2025 and is projected to reach USD...
June 24, 2026 22:30 ET | Source: Custom Market Insights

[Latest] Global Therapeutic Apheresis Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, June 25, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Therapeutic Apheresis Market Size, Trends and Insights By Product Type (Apheresis...
June 24, 2026 20:32 ET | Source: Hagens Berman Sobol Shapiro LLP

Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business – Hagens Berman

Investors who lost money in EMBC after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
June 24, 2026 16:05 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Provides Commercial and Financial Updates

No new commercial formulary additions or coverage decisions issued for neffy® (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future...
June 24, 2026 06:07 ET | Source: Bleichmar Fonti & Auld

$EMBC Stock News: Embecta Stock Dropped 57% after Insulin Pen Issues Disclosed – Investors Notified to Contact BFA Law about the Securities Class Action Lawsuit

Embecta Stock Dropped 57% after Insulin Pen Issues Disclosed – Investors Notified to Contact BFA Law about the Securities Class Action Lawsuit
June 23, 2026 17:50 ET | Source: FitRx

FitRx Expands Online Weight-Management Program With Needle-Free Oral Semaglutide Option

New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- FitRx today announced expanded availability of its online weight-management program for eligible patients who prefer a needle-free treatment pathway. ...
June 23, 2026 12:06 ET | Source: NEURORED S.A.

Neurored and DCSA Partner to Improve Freight CX Through Open Standards

Valencia, Spain, June 23, 2026 (GLOBE NEWSWIRE) -- Neurored TMS & SCM, a Salesforce-native transportation management and supply chain software provider, is partnering with DCSA through DCSA+,...
June 23, 2026 12:00 ET | Source: Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Embecta (EMBC) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 8/17/2026
June 23, 2026 10:35 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Embecta Corp. Investors

LOS ANGELES, June 23, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Embecta Corp., (“Embecta” or the "Company") (NASDAQ: EMBC) investors of a class action on behalf of investors that bought...